Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Tango Therapeutics has dosed the first subject in the Phase I/II trial assessing TNG462 in combination with Revolution Medicines' daraxonrasib or zoldonrasib for methylthioadenosine phosphorylase ...

Redwood City, Calif.-based Revolution Medicines is a late-stage clinical oncology company whose clinical-stage inhibitors include daraxonrasib, zoldonrasib, and elironrasib. Summit is a Miami-based ...

Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide ...

Daraxonrasib, a RAS(ON) multi-selective inhibitor, is a potential practice-changing medicine in Phase 3 development for RAS mutant pancreatic cancer i and non-small cell lung cancer (NSCLC).

About Daraxonrasib Daraxonrasib (RMC-6236) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a wide range of cancers driven by oncogenic RAS mutations.

Revolution Medicines, Inc. (RVMD) and Summit Therapeutics, Inc. (SMMT) have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of ...

Despite a robust cash position, Revolution Medicines' high burn rate and lofty valuation increase risk and sensitivity to ...

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ...

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of ...